PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Investors

Press Releases

All Releases
View Summary BioMarin Announces Third Quarter 2014 Financial Results
Oct 23, 2014
PDF 40.5 KB Add to Briefcase
View Summary BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
Oct 8, 2014
PDF 8.6 KB Add to Briefcase
View Summary FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets
Sep 24, 2014
PDF 9.3 KB Add to Briefcase
View Summary BioMarin to Attend Upcoming Investor Conferences
Sep 23, 2014
PDF 7.5 KB Add to Briefcase
View Summary BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines
Sep 15, 2014
PDF 9.6 KB Add to Briefcase
View Summary BioMarin to Attend Upcoming Investor Conferences in London
Sep 10, 2014
PDF 7.1 KB Add to Briefcase
View Summary BioMarin to Present at Upcoming Investor Conferences
Aug 19, 2014
PDF 7.6 KB Add to Briefcase
View Summary BioMarin Announces Second Quarter 2014 Financial Results
Jul 30, 2014
PDF 41.6 KB Add to Briefcase
View Summary BioMarin Sells Priority Review Voucher for $67.5 Million
Jul 30, 2014
PDF 8.4 KB Add to Briefcase
View Summary Sarah Cannon Research Institute UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation
Jul 23, 2014
PDF 13.4 KB Add to Briefcase
View Summary BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET
Jul 9, 2014
PDF 8.5 KB Add to Briefcase
View Summary BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome
Jul 7, 2014
PDF 15.0 KB Add to Briefcase
View Summary BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th
Jun 10, 2014
PDF 7.3 KB Add to Briefcase
View Summary BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease
May 27, 2014
PDF 12.7 KB Add to Briefcase
View Summary BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th
May 6, 2014
PDF 7.5 KB Add to Briefcase
View Summary BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress
May 1, 2014
PDF 38.8 KB Add to Briefcase
View Summary BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages
Apr 28, 2014
PDF 61.5 KB Add to Briefcase
View Summary BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET
Apr 16, 2014
PDF 8.2 KB Add to Briefcase
View Summary FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets
Apr 14, 2014
PDF 15.6 KB Add to Briefcase
View Summary BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors
Mar 21, 2014
PDF 10.2 KB Add to Briefcase
Showing 1-20 of 307 Page: 1 2 3 4 5 ... 16  Next 20
Add to Briefcase = add release to Briefcase